<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">7577478</article-id><article-id pub-id-type="pmc">2033957</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Iaffaioli</surname><given-names>R. V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tortoriello</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Facchini</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Santangelo</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>De Sena</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gesue</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bucci</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Scaramellino</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Anastasio</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Finizio</surname><given-names>A.</given-names></name></contrib><etal/></contrib-group><aff>Istituto di Medicina Interna, Universit&#x000e0; di Cagliari, Italy.</aff><pub-date pub-type="ppub"><month>11</month><year>1995</year></pub-date><volume>72</volume><issue>5</issue><fpage>1256</fpage><lpage>1258</lpage><abstract><p>Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00045-0196.tif" xlink:title="scanned-page" xlink:role="1256" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00045-0197.tif" xlink:title="scanned-page" xlink:role="1257" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00045-0198.tif" xlink:title="scanned-page" xlink:role="1258" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

